Cargando…
Effect of lurbinectedin on the QTc interval in patients with advanced solid tumors: an exposure–response analysis
PURPOSE: This study assessed the effect of lurbinectedin, a highly selective inhibitor of oncogenic transcription, on the change from baseline in Fridericia’s corrected QT interval (∆QTcF) and electrocardiography (ECG) morphological patterns, and lurbinectedin concentration–∆QTcF (C-∆QTcF) relations...
Autores principales: | Fudio, Salvador, Tabernero, Josep, Subbiah, Vivek, Chawla, Sant P., Moreno, Victor, Longo, Federico, Lopez, Rafael, Anton, Antonio, Trigo, Jose Manuel, Shapiro, Geoffrey, Jeong, Woondong, Villalobos, Victor Manuel, Lubomirov, Rubin, Fernandez-Teruel, Carlos, Alfaro, Vicente, Boni, Valentina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7801313/ https://www.ncbi.nlm.nih.gov/pubmed/33108504 http://dx.doi.org/10.1007/s00280-020-04153-6 |
Ejemplares similares
-
Integrated exposure–response analysis of efficacy and safety of lurbinectedin to support the dose regimen in small-cell lung cancer
por: Fernández-Teruel, Carlos, et al.
Publicado: (2021) -
A model-based head-to-head comparison of single-agent lurbinectedin in the pivotal ATLANTIS Study
por: Fudio, Salvador, et al.
Publicado: (2023) -
Quantitative determination of lurbinectedin, its unbound fraction and its metabolites in human plasma utilizing ultra-performance LC–MS/MS
por: King, Nicholas, et al.
Publicado: (2023) -
Antitumor activity of lurbinectedin in combination with oral capecitabine in patients with metastatic breast cancer
por: Awada, A.H., et al.
Publicado: (2022) -
Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study
por: Boni, V., et al.
Publicado: (2022)